About Mepro Pharmaceuticals Private Limited
Data last updated:
Mepro Pharmaceuticals Private Limited is a private limited company based in Surendranagar, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 31 August 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24231GJ1982PTC005451. Its GSTIN is 24AABCM4177G1ZL (Gujarat). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹5.4 Cr and a paid-up capital of ₹5.35 Cr. It is led by directors including Vijay Chhabildas Shah (Whole-Time Director) and Prakash Navinchandra Shah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1003 – GIDC Wadhwan, Surendranagar, Gujarat, India – 363035.
As per the financials filed for FY 2025, the company reported a revenue of ₹356.46 Cr, a growth of 20% compared to the previous year. For the same year it recorded a net profit of ₹35.11 Cr (net margin 9.9%) and EBITDA of ₹61.89 Cr (EBITDA margin 17.4%). Revenue has grown at a compounded annual rate (CAGR) of 19% over three years and 17% over five years.
The company has about 543 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Mepro. As per MCA filings, the company has open charges of ₹169.2 Cr and satisfied charges of ₹12.5 Cr on record. Court records list 31 cases involving the company, including 17 filed by the company and 14 filed against it; 6 cases are pending. The company has 13 deals on record (12 secondary share transfers, 1 funding round), with disclosed funding of ₹1.35 Cr; the latest was in March 2023. Its 6 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 3 smaller; the largest is Biochem Pharmaceutical Industries Limited Part IX with revenue of ₹366.61 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2023, listing 755 overdue payments to 55 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website mepro.in.
Company details
Contact details
Mepro Pharmaceuticals Private Limited's registered office is in Surendranagar, Gujarat. Its website is mepro.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address1003 – GIDC Wadhwan, Surendranagar, Gujarat, India – 363035
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Mepro Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Mepro Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Mepro Pharmaceuticals Private Limited, buy the company report.
Financials of Mepro Pharmaceuticals Private Limited
FY 2025 filings availableMepro Pharmaceuticals Private Limited reported revenue of ₹356.46 Cr (up 20% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 17% over five years, including 20% growth in the latest year. EBITDA rose 31% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹61.89 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹35.11 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 17.4% | ||||
| Net Profit Margin | 9.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Mepro Pharmaceuticals Private Limited, buy the company report.
Board of directors of Mepro Pharmaceuticals Private Limited
Mepro Pharmaceuticals has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prakash Navinchandra Shah Also directs: Mepromax Life Sciences Private Limited | Director | 17 Jul 2004 | 22 Years 3 Months | Current |
| Bharatkumar Chabildas Shah Also directs: Mepromax Life Sciences Private Limited, Sunshine Organics Pvt Ltd | Director | 31 Aug 1982 | 44 Years 1 Months | Current |
| Suresh Chhabildas Shah Also directs: Mepromax Life Sciences Private Limited | Director | 31 Aug 1982 | 44 Years 1 Months | Current |
| Vijay Chhabildas Shah | Whole-Time Director | 31 Aug 1982 | 44 Years 1 Months | Current |
| Rajesh Sumanlal Shah | Director | 30 Sep 1987 | 39 Years 0 Months | Current |
Peer comparison
Mepro Pharmaceuticals Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Biochem Pharmaceutical Industries Limited Part IX | ₹366.61 Cr (FY 2016) | 15.0% | Ahmedabad, Gujarat, India | |||
| Kopran Research Laboratories Limited | ₹365.89 Cr (FY 2025) | 13.0% | Mumbai, Maharashtra, India | |||
| Geltec Private Limited | ₹362.73 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Mepro Pharmaceuticals Private Limitedthis company | ₹356.46 Cr (FY 2025) | ₹35.11 Cr | 9.9% | 20.0% | 543 | Surendranagar, Gujarat, India |
| Bharat Parenterals Limited | ₹352 Cr (FY 2025) | 32.0% | Vadodara, Gujarat, India | |||
| Geno Pharmaceuticals Private Limited | ₹349.47 Cr (FY 2025) | 14.0% | Goa, India | |||
| Sparsh Bio-Tech Private Limited | ₹346.49 Cr (FY 2025) | -29.0% | Jamnagar, Gujarat, India |
To see the full peer comparison of Mepro Pharmaceuticals Private Limited, buy the company report.
Auditor
Mepro Pharmaceuticals Private Limited is audited by Ankush Gupta & Associates for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ankush Gupta & Associates | FY 2025 | 149227W |
Shareholding
The shareholding of Mepro Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Mepro Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Dec 2022 | 100668963 | Others | ₹5 Cr | Open | |
| 17 Oct 2019 | 100300338 | Others | ₹38.5 Cr | Open | |
| 17 Oct 2019 | 100300344 | Yes Bank Limited | ₹10 Cr | Open | |
| 21 May 2019 | 100268524 | Yes Bank Limited | ₹10 Cr | Open | |
| 21 May 2019 | 100268529 | Yes Bank Limited | ₹38.5 Cr | Open |
To see the full charge records of Mepro Pharmaceuticals Private Limited, buy the company report.
Total charge records: 11 View all charges
Deals & funding
Mepro Pharmaceuticals Private Limited has 13 deals on record (12 secondary share transfers, 1 funding round), with disclosed funding of ₹1.35 Cr; the latest was in March 2023.
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Ketan J Shah HUF, 3 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Oct 2021 | Secondary share transfer | Undisclosed | Seller: 2 individuals |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Nov 2020 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Mepro Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Mepro Pharmaceuticals Private Limited has 31 court cases on record: 17 filed by Mepro Pharmaceuticals, 14 filed against it. 6 cases are pending and 25 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 20 | 7 | 2 |
| High courts | 11 | 7 | 4 |
Cases on record (5 of 31)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Surendranagar, Gujarat | Court case (SPCS) | Filed by the company against M/S Themis Medicare Limited and 1 other | Disposed |
| High Court of Karnataka | Writ petition | Filed against the company by M/S Stallion Laboratories Pvt Ltd., | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Hab Pharmaceuticals and Research Limited | Disposed |
| Bombay High Court | Court case (S) | Filed against the company by Hab Pharmaceuticals and Research Limited | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed against the company by Baroda Pharma Pvt.Ltd. | Disposed |
To see the full case history of Mepro Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Mepro Pharmaceuticals Private Limited has 14 MSME Form 1 returns on record between 2019 and 2023, listing 755 overdue payments to 55 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 55)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Online Print and Pack Private Limited | |||
| Novex Poly Films Private Limited | |||
| Spansules Pharmatech Private Limited | |||
| Green Pack Foils Private Limited |
To see the full MSME payment records of Mepro Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Mepro Pharmaceuticals Private Limited has a workforce of 543 employees on its EPFO records as of Oct 10, 2025, across 1 active EPFO establishment.
GST
Mepro Pharmaceuticals has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AABCM4177G1ZL | Gujarat | Active | 01 Jul 2017 |
| 27AABCM4177G1ZF | Maharashtra | Active | 01 Jul 2017 |
| 27AABCM4177G2ZE | Maharashtra | Active | 01 Apr 2025 |
To see the full GST registrations and return filing status of Mepro Pharmaceuticals Private Limited, buy the company report.
Recent activity
Mepro Pharmaceuticals Private Limited has 13 board changes on record since 1982: 5 appointments and 8 cessations. The latest: Gopika Singh ceased to be Company Secretary on 31 Mar 2020.
26 earlier events are in the company report.
Frequently asked questions
Mepro Pharmaceuticals is an active private limited company based in Surendranagar, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 31 August 1982 (44+ years old) and is registered under CIN U24231GJ1982PTC005451.
Mepro Pharmaceuticals has 5 current directors:
- Vijay Chhabildas Shah - Whole-Time Director
- Prakash Navinchandra Shah - Director
- Bharatkumar Chabildas Shah - Director
- Suresh Chhabildas Shah - Director
- Rajesh Sumanlal Shah - Director
The latest financial statements of Mepro Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Mepro Pharmaceuticals is 24AABCM4177G1ZL, registered in Gujarat. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 27AABCM4177G1ZF (Maharashtra), 27AABCM4177G2ZE (Maharashtra).
The CIN (Corporate Identification Number) of Mepro Pharmaceuticals is U24231GJ1982PTC005451. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Mepro Pharmaceuticals has 31 court cases on record: 17 filed by the company and 14 filed against it. 6 are pending. Most are in the district courts.
Mepro Pharmaceuticals was incorporated on 31 August 1982, making it 44+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Mepro Pharmaceuticals has 13 deals on record (12 secondary share transfers, 1 funding round), with disclosed funding of ₹1.35 Cr; the latest was in March 2023.
The peers of Mepro Pharmaceuticals by revenue are Biochem Pharmaceutical Industries Limited Part IX, Kopran Research Laboratories Limited, Geltec Private Limited, Bharat Parenterals Limited, Geno Pharmaceuticals Private Limited and 1 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Gopika Singh ceased to be Company Secretary on 31 Mar 2020. Bharatkumar Chabildas Shah ceased to be Whole-Time Director on 30 Sep 2019. Prakash Navinchandra Shah ceased to be Whole-Time Director on 30 Sep 2019. Mepro Pharmaceuticals has 13 board changes on record in total.
Mepro Pharmaceuticals has 14 MSME Form 1 returns on record between 2019 and 2023, listing 755 overdue payments to 55 micro and small suppliers. The latest return was filed on 27 Aug 2023.
Mepro Pharmaceuticals can be reached through the website mepro.in. Its registered office is in Surendranagar, Gujarat, India.